HUP0201310A2 - Szelektív PDE10-inhibitorok terápiás alkalmazása - Google Patents
Szelektív PDE10-inhibitorok terápiás alkalmazásaInfo
- Publication number
- HUP0201310A2 HUP0201310A2 HU0201310A HUP0201310A HUP0201310A2 HU P0201310 A2 HUP0201310 A2 HU P0201310A2 HU 0201310 A HU0201310 A HU 0201310A HU P0201310 A HUP0201310 A HU P0201310A HU P0201310 A2 HUP0201310 A2 HU P0201310A2
- Authority
- HU
- Hungary
- Prior art keywords
- pde10 inhibitors
- therapeutic use
- selective pde10
- disorders
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000003930 cognitive ability Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát szelektív PDE10-inhibitorok alkalmazása képezi aközponti idegrendszer rendellenességeinek kezelésére, közelebbrőlneurológiai és pszichiátriai rendellenességek, például szimptómakéntpszichózis és deficiens kognitív képességgel járó rendellenességekkezelésére. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28514801P | 2001-04-20 | 2001-04-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0201310D0 HU0201310D0 (hu) | 2002-06-29 |
HUP0201310A2 true HUP0201310A2 (hu) | 2003-02-28 |
HUP0201310A3 HUP0201310A3 (en) | 2008-10-28 |
Family
ID=23092939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0201310A HUP0201310A3 (en) | 2001-04-20 | 2002-04-19 | Therapeutic use of selective pde10 inhibitors |
Country Status (13)
Country | Link |
---|---|
US (1) | US20030008806A1 (hu) |
EP (1) | EP1250923A3 (hu) |
JP (1) | JP3839343B2 (hu) |
KR (2) | KR20020082136A (hu) |
CN (2) | CN1840181A (hu) |
AU (1) | AU3440902A (hu) |
CA (1) | CA2382326A1 (hu) |
HK (1) | HK1048070A1 (hu) |
HU (1) | HUP0201310A3 (hu) |
IL (1) | IL149106A0 (hu) |
NZ (1) | NZ518478A (hu) |
PL (1) | PL353535A1 (hu) |
ZA (1) | ZA200203123B (hu) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10130151A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Neue Verwendung für PDE 10A-Inhibitoren |
DE10230604A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
US20060110783A1 (en) * | 2002-11-08 | 2006-05-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a) |
WO2004045508A2 (en) * | 2002-11-15 | 2004-06-03 | Merck & Co., Inc. | Use of pde4 inhibitors as adjunct therapy for psychiatric disorders |
US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
WO2005002579A1 (en) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
WO2005003129A1 (en) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines as pde10 inhibitors |
US20090162286A1 (en) * | 2004-06-07 | 2009-06-25 | Pfizer Inc. | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2006089815A1 (en) * | 2005-01-12 | 2006-08-31 | Nycomed Gmbh | Novel pyrrolodihydroisoquinolines as pde10 inhibitors |
WO2007022280A1 (en) * | 2005-08-16 | 2007-02-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
US20100056791A1 (en) * | 2006-09-01 | 2010-03-04 | Yasushi Kohno | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
JPWO2008029829A1 (ja) * | 2006-09-06 | 2010-01-21 | 杏林製薬株式会社 | ピラゾロピリジン誘導体及びそれらを有効成分とするホスホジエステラーゼ(pde)阻害剤 |
US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
US7858620B2 (en) | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
UA102693C2 (ru) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
JPWO2010035745A1 (ja) * | 2008-09-25 | 2012-02-23 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするpde阻害剤 |
TW201020233A (en) * | 2008-10-09 | 2010-06-01 | Kyorin Seiyaku Kk | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
KR101478889B1 (ko) | 2010-02-26 | 2015-01-02 | 미쓰비시 타나베 파마 코퍼레이션 | 피라졸로피리미딘 화합물 및 pde10 억제제로서의 그의 용도 |
TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
WO2014133046A1 (ja) | 2013-02-27 | 2014-09-04 | 持田製薬株式会社 | 新規ピラゾール誘導体 |
WO2015006689A1 (en) * | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3224100A1 (de) * | 1982-06-29 | 1983-12-29 | Michael 6950 Schriesheim Long | Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen |
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
JP3276762B2 (ja) * | 1993-12-28 | 2002-04-22 | 日本臓器製薬株式会社 | イソキノリン誘導体を含有する医薬組成物 |
HUT71408A (en) * | 1994-01-14 | 1995-11-28 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission |
JP3598116B2 (ja) * | 1994-04-15 | 2004-12-08 | 雅臣 伊豫 | 遅発性ジスキネジアの治療用医薬組成物とその利用 |
AU2252297A (en) * | 1996-01-31 | 1997-08-22 | Technology Licensing Co., L.L.C. | Method of diagnosis and treatment and related compositions and apparatus |
KR0177295B1 (ko) * | 1996-02-28 | 1999-03-20 | 정명식 | 이소퀴놀린 화합물을 함유하는 항우울제 |
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
JP2002504341A (ja) * | 1998-02-23 | 2002-02-12 | アイコス コーポレイション | ホスホジエステラーゼ10 |
EP1218003A4 (en) * | 1999-09-13 | 2004-02-11 | David M Swope | COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY |
WO2001024781A2 (en) * | 1999-10-07 | 2001-04-12 | Novaneuron Inc. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
-
2002
- 2002-04-11 IL IL14910602A patent/IL149106A0/xx unknown
- 2002-04-17 EP EP02252729A patent/EP1250923A3/en not_active Withdrawn
- 2002-04-18 CA CA002382326A patent/CA2382326A1/en not_active Abandoned
- 2002-04-18 AU AU34409/02A patent/AU3440902A/en not_active Abandoned
- 2002-04-19 JP JP2002117635A patent/JP3839343B2/ja not_active Expired - Fee Related
- 2002-04-19 HU HU0201310A patent/HUP0201310A3/hu unknown
- 2002-04-19 NZ NZ518478A patent/NZ518478A/en unknown
- 2002-04-19 US US10/126,113 patent/US20030008806A1/en not_active Abandoned
- 2002-04-19 KR KR1020020021667A patent/KR20020082136A/ko not_active Application Discontinuation
- 2002-04-19 PL PL02353535A patent/PL353535A1/xx not_active Application Discontinuation
- 2002-04-19 ZA ZA200203123A patent/ZA200203123B/xx unknown
- 2002-04-22 CN CNA2006100045277A patent/CN1840181A/zh active Pending
- 2002-04-22 CN CN02118061A patent/CN1382490A/zh active Pending
-
2003
- 2003-01-14 HK HK03100308.4A patent/HK1048070A1/zh unknown
-
2005
- 2005-12-27 KR KR1020050130283A patent/KR20060002003A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2382326A1 (en) | 2002-10-20 |
PL353535A1 (en) | 2002-10-21 |
ZA200203123B (en) | 2003-10-20 |
JP2002363103A (ja) | 2002-12-18 |
HU0201310D0 (hu) | 2002-06-29 |
CN1840181A (zh) | 2006-10-04 |
EP1250923A2 (en) | 2002-10-23 |
JP3839343B2 (ja) | 2006-11-01 |
EP1250923A3 (en) | 2003-01-15 |
HUP0201310A3 (en) | 2008-10-28 |
KR20060002003A (ko) | 2006-01-06 |
US20030008806A1 (en) | 2003-01-09 |
NZ518478A (en) | 2004-04-30 |
HK1048070A1 (zh) | 2003-03-21 |
AU3440902A (en) | 2002-10-24 |
IL149106A0 (en) | 2002-11-10 |
CN1382490A (zh) | 2002-12-04 |
KR20020082136A (ko) | 2002-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0201310A2 (hu) | Szelektív PDE10-inhibitorok terápiás alkalmazása | |
PT1242415E (pt) | Derivados de 3-tiazol-4-il-pirrolidina como inibidores de fosfodiesterase especificos de mfa | |
IS7941A (is) | Bensasepínafleiður til að meðhöndla taugasjúkdóma | |
IL150313A0 (en) | Pyrrolidine derivatives as cyclic amp -specific phosphodiesterase inhibitors | |
HK1152243A1 (en) | Vegf for use in the treatment of central nervous system disorders vegf | |
EE200300559A (et) | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks | |
EP1434801A4 (en) | TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
AU2003249983A8 (en) | Piperidines useful for the treatment of central nervous system disorders | |
HK1054039A1 (en) | Substituded beta-carbolines | |
SI1474416T1 (sl) | Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj | |
MY124786A (en) | Bis-arylsulfones | |
AU2002356525A1 (en) | Substituted amines for the treatment of neurological disorders | |
NO20043085L (no) | Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet | |
MXPA02006206A (es) | Pirrolidinas que inhiben la pde camp-especifica. | |
IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
GB0207653D0 (en) | Methods of using lamellar bodies for therapeutic purposes | |
PT1244649E (pt) | Inibidores de fosfodiesterase especificos de mfa ciclica | |
WO2002060373A3 (en) | Indole derivatives and their uses as heparanase inhibitors | |
IL181713A0 (en) | Use of il-17f for the treatment and/or prevention of neurological diseases | |
TWI245756B (en) | Improved process for the preparation of 1,3-substituted indenes | |
WO2004016604A3 (en) | Azabicyclic compounds are central nervous system active agents | |
MXPA04004757A (es) | Uso de una ascomicina para el tratamiento de blefaritis. | |
HK1088317A1 (en) | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system | |
AU2002322397A1 (en) | Combination therapy for the treatment of neurological disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |